Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients
Objectives: The UMACOACH Lymphoma is a multidisciplinary monitoring program for patients initiating a first highly haematotoxic treatment for Hodgkin or non-Hodgkin lymphoma. Patient follow-up is based on consultation with a pharmacist and planed phone calls by nurses supervised by a clinical haemat...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/10/2532 |
| _version_ | 1797500954904363008 |
|---|---|
| author | Madeline Devaux Mathieu Boulin Morgane Mounier Denis Caillot Nuri Ahwij Adélie Herbin Jean Noël Bastie Camille Favennec Philippine Robert Pauline Pistre Stephanie Bost Pauline Amiot Laurence Jacquesson Olivier Casasnovas Cédric Rossi Pauline Gueneau |
| author_facet | Madeline Devaux Mathieu Boulin Morgane Mounier Denis Caillot Nuri Ahwij Adélie Herbin Jean Noël Bastie Camille Favennec Philippine Robert Pauline Pistre Stephanie Bost Pauline Amiot Laurence Jacquesson Olivier Casasnovas Cédric Rossi Pauline Gueneau |
| author_sort | Madeline Devaux |
| collection | DOAJ |
| description | Objectives: The UMACOACH Lymphoma is a multidisciplinary monitoring program for patients initiating a first highly haematotoxic treatment for Hodgkin or non-Hodgkin lymphoma. Patient follow-up is based on consultation with a pharmacist and planed phone calls by nurses supervised by a clinical haematologist. Our objective was to assess effectiveness and cost of the UMACOACH Lymphoma Program (ULP) and to investigate patient satisfaction and quality of life (QoL). Methods: This French monocentric case-control study included all patients enrolled in the ULP over a one-year period (cases) matched with retrospective patients receiving usual care (controls). Numbers of adverse events (AEs), re-hospitalisations, average relative dose intensity (ARDI), treatment response and survival were compared between the two groups. Among cases, patient satisfaction and QoL using the EORTC-QLQC30 questionnaire before and after treatment were evaluated. Results: Seventy-eight cases were matched to 78 controls. Twenty-six percent grade 3–4 AEs were observed in cases versus 38% in controls (<i>p</i> = 0.001). There were 76 and 88 re-hospitalisations in the case and control groups, respectively (<i>p</i> = 0.217). ARDI > 85% was observed in 92% and 82% of cases and controls, respectively (<i>p</i> = 0.138). No differences were observed in terms of treatment responses and survival. Estimated cost savings were of EUR 81,782 in favour of the case group. An improvement of 5.1 points was observed in the total QoL score before and after treatment in cases. Conclusions: A nurse–pharmacist–haematologist collaboration seems to be promising to reduce grade 3–4 AEs in HL and NHL patients receiving highly haematotoxic chemotherapy regimens. Cost savings from hospitalisation being avoided were also shown. |
| first_indexed | 2024-03-10T03:11:18Z |
| format | Article |
| id | doaj.art-2131eb2b3f85423ab00cf542fae01369 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T03:11:18Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-2131eb2b3f85423ab00cf542fae013692023-11-23T10:24:31ZengMDPI AGCancers2072-66942022-05-011410253210.3390/cancers14102532Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma PatientsMadeline Devaux0Mathieu Boulin1Morgane Mounier2Denis Caillot3Nuri Ahwij4Adélie Herbin5Jean Noël Bastie6Camille Favennec7Philippine Robert8Pauline Pistre9Stephanie Bost10Pauline Amiot11Laurence Jacquesson12Olivier Casasnovas13Cédric Rossi14Pauline Gueneau15Department of Pharmacy, University Hospital, F-21000 Dijon, FranceDepartment of Pharmacy, University Hospital and EPICAD LNC UMR1231, University of Burgundy & Franche Comte, F-21000 Dijon, FranceRegistre des Hémopathies Malignes de Côte d’Or, Dijon-Bourgogne University Hospital, F-21000 Dijon, FranceDepartment of Clinical Hematology, University Hospital INSERM UMR1231 and SAPHIIR-UMR 1231, University of Burgundy & Franche Comte, F-21000 Dijon, FranceDepartment of Clinical Hematology, University Hospital, F-21000 Dijon, FranceDepartment of Clinical Hematology, University Hospital, F-21000 Dijon, FranceDepartment of Clinical Hematology, University Hospital, F-21000 Dijon, FranceDepartment of Clinical Hematology, University Hospital, F-21000 Dijon, FranceDepartment of Clinical Hematology, University Hospital, F-21000 Dijon, FranceDepartment of Pharmacy, University Hospital, F-21000 Dijon, FranceDepartment of Pharmacy, University Hospital, F-21000 Dijon, FranceDepartment of Clinical Hematology, University Hospital, F-21000 Dijon, FranceDepartment of Clinical Hematology, University Hospital, F-21000 Dijon, FranceDepartment of Clinical Hematology, University Hospital INSERM UMR1231 and SAPHIIR-UMR 1231, University of Burgundy & Franche Comte, F-21000 Dijon, FranceDepartment of Clinical Hematology, University Hospital and SAPHIIR-UMR 1231, University of Burgundy & Franche Comte, F-21000 Dijon, FranceDepartment of Pharmacy, University Hospital, F-21000 Dijon, FranceObjectives: The UMACOACH Lymphoma is a multidisciplinary monitoring program for patients initiating a first highly haematotoxic treatment for Hodgkin or non-Hodgkin lymphoma. Patient follow-up is based on consultation with a pharmacist and planed phone calls by nurses supervised by a clinical haematologist. Our objective was to assess effectiveness and cost of the UMACOACH Lymphoma Program (ULP) and to investigate patient satisfaction and quality of life (QoL). Methods: This French monocentric case-control study included all patients enrolled in the ULP over a one-year period (cases) matched with retrospective patients receiving usual care (controls). Numbers of adverse events (AEs), re-hospitalisations, average relative dose intensity (ARDI), treatment response and survival were compared between the two groups. Among cases, patient satisfaction and QoL using the EORTC-QLQC30 questionnaire before and after treatment were evaluated. Results: Seventy-eight cases were matched to 78 controls. Twenty-six percent grade 3–4 AEs were observed in cases versus 38% in controls (<i>p</i> = 0.001). There were 76 and 88 re-hospitalisations in the case and control groups, respectively (<i>p</i> = 0.217). ARDI > 85% was observed in 92% and 82% of cases and controls, respectively (<i>p</i> = 0.138). No differences were observed in terms of treatment responses and survival. Estimated cost savings were of EUR 81,782 in favour of the case group. An improvement of 5.1 points was observed in the total QoL score before and after treatment in cases. Conclusions: A nurse–pharmacist–haematologist collaboration seems to be promising to reduce grade 3–4 AEs in HL and NHL patients receiving highly haematotoxic chemotherapy regimens. Cost savings from hospitalisation being avoided were also shown.https://www.mdpi.com/2072-6694/14/10/2532lymphomafollow-upnursepharmacistimmunochemotherapyhaematotoxicity |
| spellingShingle | Madeline Devaux Mathieu Boulin Morgane Mounier Denis Caillot Nuri Ahwij Adélie Herbin Jean Noël Bastie Camille Favennec Philippine Robert Pauline Pistre Stephanie Bost Pauline Amiot Laurence Jacquesson Olivier Casasnovas Cédric Rossi Pauline Gueneau Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients Cancers lymphoma follow-up nurse pharmacist immunochemotherapy haematotoxicity |
| title | Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients |
| title_full | Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients |
| title_fullStr | Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients |
| title_full_unstemmed | Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients |
| title_short | Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients |
| title_sort | clinical and economic impact of a multidisciplinary follow up program in lymphoma patients |
| topic | lymphoma follow-up nurse pharmacist immunochemotherapy haematotoxicity |
| url | https://www.mdpi.com/2072-6694/14/10/2532 |
| work_keys_str_mv | AT madelinedevaux clinicalandeconomicimpactofamultidisciplinaryfollowupprograminlymphomapatients AT mathieuboulin clinicalandeconomicimpactofamultidisciplinaryfollowupprograminlymphomapatients AT morganemounier clinicalandeconomicimpactofamultidisciplinaryfollowupprograminlymphomapatients AT deniscaillot clinicalandeconomicimpactofamultidisciplinaryfollowupprograminlymphomapatients AT nuriahwij clinicalandeconomicimpactofamultidisciplinaryfollowupprograminlymphomapatients AT adelieherbin clinicalandeconomicimpactofamultidisciplinaryfollowupprograminlymphomapatients AT jeannoelbastie clinicalandeconomicimpactofamultidisciplinaryfollowupprograminlymphomapatients AT camillefavennec clinicalandeconomicimpactofamultidisciplinaryfollowupprograminlymphomapatients AT philippinerobert clinicalandeconomicimpactofamultidisciplinaryfollowupprograminlymphomapatients AT paulinepistre clinicalandeconomicimpactofamultidisciplinaryfollowupprograminlymphomapatients AT stephaniebost clinicalandeconomicimpactofamultidisciplinaryfollowupprograminlymphomapatients AT paulineamiot clinicalandeconomicimpactofamultidisciplinaryfollowupprograminlymphomapatients AT laurencejacquesson clinicalandeconomicimpactofamultidisciplinaryfollowupprograminlymphomapatients AT oliviercasasnovas clinicalandeconomicimpactofamultidisciplinaryfollowupprograminlymphomapatients AT cedricrossi clinicalandeconomicimpactofamultidisciplinaryfollowupprograminlymphomapatients AT paulinegueneau clinicalandeconomicimpactofamultidisciplinaryfollowupprograminlymphomapatients |